Page 1 of 2



Intended Use

The **PreventID® Ovulation** (<u>test devices</u>) is a rapid test for the detection of luteinising hormone (LH) in urine. An increase in LH triggers ovulation and therefore marks a woman's most fertile day of the month. Because the ovule can be fertilised only 6 to 24 hours after ovulation, the **PreventID® Ovulation** is an important aid to pregnancy planning. For professional use only.

Materials

Materials Provided:

- test devices (with sample droppers), individually packed TEST
- manua

Materials Required but not Provided: Timer or stop watch, sample container

Storage and Stability

Store the test between 4 °C and 30 °C; do not freeze. The test device is sensitive to humidity as well as to heat. Perform the test immediately after removing the test device from the pouch. Do not use it beyond the expiry date.

Precautions

- 1. For in vitro diagnostic use only.
- 2. Do not use beyond the expiry date.
- 3. Read the manual carefully before performing the test.
- 4. Perform the test immediately after removing the test device from the pouch.
- 5. During performing the test do not eat or smoke.
- 6. Wear protective gear such as disposable gloves, lab coat etc. and avoid spilling of sample material. If sample material has been spilled, clean the site thoroughly with disinfectant.
- 7. Clean all contaminated surfaces carefully. Dispose all test components and samples in conventional garbage.
- Do not use test if the pouch is torn or if the membrane of the test device is visibly damaged.
- 9. If you have any questions please contact Preventis GmbH.

When to begin testing?

- You may do this test at any time of the day, but you should test at approximately the same time each day. Reduce your liquid intake for 2 hours before testing.
- To decide when to begin testing, determine the length of your normal menstrual cycle. The length of your cycle is from the beginning of one period to the beginning of the next (count the first day of bleeding or spotting as day 1).
- If your cycle length is irregular, that is, if it varies by more than a few days each month, take the average number of days for the last 3 months. Use the chart to work out the day you should begin testing. The day you begin testing is listed opposite the number of days in your normal cycle (Table 1).
- For example, if your period normally begins every 28 days, you should begin testing 11 days after the first day of your last period.
- For example: If the 2nd day of the month is the first day of menstrual bleeding (day 1), then the 12th day of the month is day 11 of your cycle. This is the day to begin testing (Table 2).

Lenght of normal cycle (number of days)	Start testing after this number of days in current menstrual cycle		
21	5		
22	5		
23	6		
24	7		
25	8		
26	9		
27	10		
28	11		
29	12		
30	13		
31	14		
32	15		
33	16		
34	17		
35	18		
36	19		
37	20		
38	21		
39	22		
40	23		


Table 1: Test begin in relation to cycle length

Sun	Mon	Tue	Wed	Thu	Fri	Sat
1	2 1st day of cycle	3	4	5	6	7
8	9	10	11	12 11 th day of cycle	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31				

Table 2: Example of how to calculate test begin in the calendar

Test Procedure

- 1. Collect urine in a sample container.
- 2. Remove the test device from the pouch, and place it on a flat, dry surface.
- 3. Holding the sample dropper above the test device, squeeze **2 drops of urine** into the sample application window (Fig. 1).
- 4. As the test begins to work, you will see a purple coloured line move across the result window located in the center of the test device.
- 5. Interpret test results after 5 minutes.





Page 2 of 2

Test Interpretation (Fig. 2)

As the test kit begins to work, a coloured line will appear at the left section of the result window to show that the test is working properly. This line is the **control line (C)**.

The right section of the result window indicates the test results. If another coloured line appears at the right section of the result window, this line is the **test line** (T).


The control line (C) is used as a reference and for procedural control to determine if the test reagent is working properly.

Positive result: The presence of two coloured lines of similar colour and darkness within the result window, no matter which one appears first, means that an increase in LH is detected. The test line (T) may be darker than the control line (C) (Fia. 2a).

Negative result: The presence of a coloured control line (C) and a lighter coloured test line (T) means that an increase in LH is not detected.

The presence of only one coloured control line (C) within the result window indicates that no LH increase has been detected (Fia. 2b).

Invalid result: The test result is considered invalid if no coloured line is visible within the result window. Not following the directions correctly or using a test after the expiry date can cause invalid results. Repeat the test using a new test device.



Test characteristics

Clinical sensitivity

Clinical sensitivity for **PreventID® Ovulation** was tested against the reference test Ultimed LH test, which is considered to be the gold standard for this parameter. The result shows that **PreventID® Ovulation** LH test (test devices) is in 100 % agreement with Ultimed LH test.

- Clinical sensitivity = 100 %
- Clinical specifity = 100 %

Analytical sensitivity

To determine the precise sensitivity of the **PreventID® Ovulation** test, urine sample devoid of LH are used together with Bio-Rad fertility controls to pre-set LH concentration levels. Specimens are prepared into 4 groups, LH-negative, 15 mIU/mL, 25 mIU/mL and 50 mIU/mL. The summarised data showed the sensitivity of **PreventID® Ovulation** test (test devices) is determined to be at 25mIU/ml (50 tests were used for each LH concentration level for each of the LOT tested).

Interference tests

Potentially interfering chemical substances such as pain medication, lipids, hemoglobin, bilirubin and glucose were supplemented to clinically defined negative normal urine and clinically

defined positive urine specimens. These samples were tested using the **PreventID® Ovulation** test by a replicate of 10. A sample was classified negative, when no purple colour band was visible for the LH test line but the purple colour "C" control line being visible within 5 minutes. A sample was classified positive, when both the control and test line were visible within 5 minutes.

Tests were done with the following substances: Acetamiophen, 20 mg/dL, Acetyl salicylic Acid, 20 mg/dL, Ascorbic Acid, 20 mg/ dL, Atropine, 20 mg/dL, Bilirubin, 60 mg/dL, Caffeine, 20 mg/dL, Creatinine, 20 mg/dL, Gentesic Acid, 20 mg/dL, Glucose, 2000 mg/dL, Hemoglobin, 500 mg/dL, Ketones, 40 mg/dL, Lithium Heparin, 3 mg/dL, Mestranol, 3 mg/dL, Nitrite, 20 mg/dL, Penicillin, 40,000 U/dL, Sodium Heparin, 3 mg/dL, Tetracycline, 20 mg/dL as well as Fatty acids, 300 mg/dL, Triglyceride, 250 mg/dL, Sterol esters, 300 mg/dL, Monoacylglycerols, 300 mg/dL, Diacylglycerols, 300mg/dL, Glycerophospholipids, 300mg/dL, Glyceroglycolipids, 300mg/dL, Sphingomyelin, 3020mg/dL, Glycosphingolipids, 300mg/dL. In conclusion, none of the above tested substances showed any interference with neither a clinically defined negative nor a positive specimen. Negative urine samples with supplementation of potentially interfering substances gave consistently negative test results, whereas urine samples positive to LH scored consistently positive.

Cross reactivity

Urine specimens devoid of LH were spiked with hCG (up to 10,000 mIU/mL), FSH (up to 1000 mIU/mL) and TSH (up to 1000 μ IU/mL), these samples were then tested with **PreventID® Ovulation** tests.

At the levels tested, none of the hormones/substances cross reacted with the **PreventID® Ovulation** test (test devices).

Test Limitations

Use the test strip only once. Test results are only reliable if you follow the instructions for use carefully. Although the **PreventID® Ovulation** is highly accurate in detecting ovulation, a low incidence of false results (positive when no ovulation exists or negative when ovulation is present) can occur. Other clinically available tests are required if questionable results are obtained. As with all diagnostic tests, a definitive clinical diagnosis should not be based on the results of a single test, but should only be made by the physician after all clinical and laboratory findings the **PreventID® Ovulation** should not be used for contraception.

References

- 10. Apter D, Cacciatore B, Alfthan H, et al, "Serum Luteinizing Hormone Concentrations Increase 100-Fold in Females From 7 Years to Adulthood, as measured by Tim-Resolved Immunofluorometric Assay" J Clin Endocrinol Metab, 1989, 68 (1):53-7.
- Nippoldt TB, Reame NE, Reich RP, et al., "The Roles of Estradiol and Progesterone in Decreasing Luteinizing Hormone Pulse Frequency in the Luteal Phase of the Menstrual Cycle." J Clin Endocrinol Metab, 1989, 69 (1): 67-76.

CE

Status: 2018-12-03

US: all products: Research Use Only. Not for use in diagnostic procedures.

1	Temperature limitation	ш	Manufacturer		
IVD	In vitro diagnostic device	LOT	Lot number		
REF	Catalogue number		Expiry date		
→REF	To be used with	(3)	Do not reuse		
[]i	Read user instructions	Σ n	Contains sufficient for <n> tests</n>		
Keep away from sunlight					

Immundiagnostik AG Stubenwald-Allee 8a 64625 Bensheim, Germany Distributed by: **Preventis GmbH**Stubenwald-Allee 8a

64625 Bensheim, Germany
Phone: +49 6251 70711-0

Fax:+49 6251 70711-25
info@preventis.com
www.preventis.com

